Sunday 18 October 2026
Export NXL’s income statement to Excel — free account
Nexalin Technology, Inc.
NXL Healthcare Medical Devices
Nexalin Technology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $301,600.00, up 78.8% from fiscal 2024. In the quarter to June 2026, revenue fell 82.7%, EPS fell 10.0% and free cash flow fell 97.2%, each against the same quarter a year earlier.
2.35
0.10
−4.08%
Follow NXL
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 4 | 3 | 4 | 4 | 5 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | — | (12.11) | (29.65) | (5.22) | (26.89) |
P/S ratio |
0.00 | 0.00 | 0.00 | 3.31 | 26.43 | 150.63 | 30.30 |
Altman Z″-Score (non-manufacturers) |
(2,004.13) | (2,045.67) | (374.17) | (25.63) | (66.35) | (65.32) | (68.21) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (103.50) | (30.87) | 4.76 | 13.29 | (6.22) | (2.86) |
P/Operating CF |
(67.87) | (67.87) | (67.87) | (4.82) | (2.91) | (22.40) | (7.96) |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.80 | 0.91 | 6.91 | 2.44 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.80 | 0.94 | 7.44 | 2.68 |
EV/Sales |
0.00 | 0.00 | 0.00 | (1.98) | (0.16) | 130.03 | 17.97 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 1.43 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(7.58) | (7.58) | (7.58) | 1.18 | 0.00 | (5.56) | (1.09) |
EV/FCF |
(7.58) | (7.58) | (7.58) | 1.18 | 0.00 | (1.99) | (0.45) |
Quick Ratio |
0.07 | 0.05 | 0.29 | 3.59 | 6.95 | 6.39 | 4.29 |
Current Ratio |
0.11 | 0.07 | 0.32 | 3.81 | 8.06 | 7.25 | 4.85 |
Net Debt/EBITDA |
(0.53) | 0.02 | 0.11 | 3.82 | 0.52 | 0.45 | 0.44 |
Debt/Assets |
744.18% | 4.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(0.71) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 2.10 | 0.33 | 0.32 | 0.02 | 0.04 | 0.07 |
Operating CF/Net income |
0.14 | 0.25 | 0.18 | 1.31 | 0.83 | 0.52 | 0.60 |
Capex/Depreciation |
0.00 | (0.06) | 0.00 | (13,589.80) | (27.81) | (11.28) | (4.51) |
Interest Coverage |
(36.20) | (41.87) | (73.13) | (30.86) | (146.81) | 2,423.31 | 1,023.28 |
| 0.00% | 245.77% | 371.49% | (89.43%) | (107.05%) | (221.06%) | (221.50%) | |
| 0.00% | (2,946.75%) | (1,393.72%) | (41.48%) | (84.03%) | (193.70%) | (185.64%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (1,378.85%) | (2,471.51%) | (21,146.42%) |
Return on Tangible Assets |
540.26% | 235.03% | 377.54% | (31.00%) | (154.72%) | (222.80%) | (240.98%) |
Average Days of Receivables |
10.03 | 9.92 | 41.29 | 1.35 | 30.99 | 28.13 | 98.75 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 38.67% | 1,736.04% | 705.93% | 359.25% |
Selling, General and Administrative Expense of Revenue |
701.69% | 1,429.52% | 4,261.76% | 211.23% | 3,486.45% | 3,969.12% | 2,502.52% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | 0.07 |
Share Based Compensation of Revenue |
0.00% | 806.71% | 3,107.56% | 20.49% | 2,180.13% | 2,110.55% | 1,035.58% |
Graham Net Nets |
0.01 | 0.01 | 0.01 | 1.25 | 1.03 | 0.13 | 0.37 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(56.69%) | (56.69%) | (56.69%) | (40.15%) | (155.93%) | (29.74%) | (91.49%) |
Free Cash Flow Yield |
(13.10%) | (13.10%) | (13.10%) | (50.69%) | (370.76%) | (43.42%) | (131.04%) |
Revenue per Share |
0.03 | 2.04 | 1.02 | 7.12 | 0.45 | 0.55 | 0.55 |
Operating CF per Share |
(0.09) | (7.24) | (7.60) | (11.94) | (15.65) | (12.85) | (9.08) |
Capex per Share |
0.00 | 0.00 | 0.00 | (36.61) | (0.49) | (0.55) | (0.18) |
Free Cash Flow per Share |
(0.09) | (7.24) | (7.60) | (48.55) | (16.14) | (13.41) | (9.26) |
Cash per Share |
0.01 | 0.66 | 4.67 | 37.68 | 12.03 | 11.34 | 6.82 |
Shareholders Equity per Share |
(0.16) | (13.33) | (11.87) | 29.52 | 13.09 | 11.98 | 6.87 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(0.16) | (13.33) | (11.87) | 29.52 | 13.09 | 11.98 | 6.87 |
Free Cash Flow |
(0.68) | (0.86) | (1.08) | (9.01) | (3.95) | (4.11) | (5.05) |
Working Capital |
(0.93) | (1.45) | (1.61) | 5.48 | 3.00 | 3.41 | 3.41 |
Capital Expenditures |
— | 0.00 | — | (6.79) | (0.12) | (0.17) | (0.10) |
Net Current Asset Value |
(1.18) | (1.59) | (1.68) | 5.47 | 3.00 | 3.41 | 3.41 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 1.43 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 5.14 | 1.08 | 1.01 | 0.32 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||
Depreciation/Fixed assets |
0.36 | 5.81 | 0.50 | 1.00 | 0.00 | 0.00 | 0.00 |
Cash ROIC |
243.29% | 57.36% | 105.56% | (72.24%) | (64.26%) | (57.50%) | (67.65%) |
Accounts Receivable Turnover |
0.00 | 39.50 | 12.59 | 124.66 | 15.48 | 15.06 | 6.38 |
Accounts Payable Turnover |
0.00 | 0.07 | 0.03 | 0.48 | 0.06 | 0.23 | 0.31 |
Inventory Turnover |
0.00 | 1.31 | 0.79 | 3.91 | 0.17 | 0.22 | 0.40 |
Average Days of Payables |
542.82 | 5,804.76 | 14,391.92 | 661.66 | 2,265.27 | 1,554.74 | 1,454.06 |
Days of Inventory on Hand |
36.13 | 285.71 | 535.56 | 155.17 | 2,221.25 | 1,741.23 | 781.72 |
Average Receivables |
— | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.05 |
Average Payables |
— | 0.39 | 0.65 | 0.75 | 0.41 | 0.16 | 0.20 |
Average Inventory |
— | 0.02 | 0.03 | 0.09 | 0.16 | 0.17 | 0.15 |
Average Assets |
— | 0.12 | 0.44 | 4.09 | 5.53 | 3.93 | 4.43 |
Average Common Equity |
— | (1.38) | (1.64) | 1.90 | 4.34 | 3.44 | 3.71 |
Columns are period end dates · fundamentals updated 2 Oct 2026